G1 Therapeutics (GTHX) Misses Q3 EPS by 1c; Offers FY23 COSELA Sales Guidance

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q3 EPS of ($0.35), $0.01 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.24 million.

The Company expects to generate between $44 million and $47 million in COSELA net revenue in 2023

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c